EA029499B9 - Ингибиторы rorc2 и способы их применения - Google Patents

Ингибиторы rorc2 и способы их применения

Info

Publication number
EA029499B9
EA029499B9 EA201690039A EA201690039A EA029499B9 EA 029499 B9 EA029499 B9 EA 029499B9 EA 201690039 A EA201690039 A EA 201690039A EA 201690039 A EA201690039 A EA 201690039A EA 029499 B9 EA029499 B9 EA 029499B9
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
rorc2
inhibitors
compounds
rorc2 inhibitors
Prior art date
Application number
EA201690039A
Other languages
English (en)
Other versions
EA201690039A1 (ru
EA029499B1 (ru
Inventor
Джеймс Роберт Блинн
Эндрю Кристофер Флик
Горан Маттиас Веннерстол
Питер Джонс
Неелу Кайла
Джеймс Ричард мл. Кифер
Рави Дж. Курумбаил
Скот Ричард Менте
Марвин Джей Мейерс
Марк Эдвард Шнуте
Атли Тораренсен
Ли Син
Эдуард Замаратски
Кристоф Вольфганг Запф
Original Assignee
Пфайзер Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк filed Critical Пфайзер Инк
Publication of EA201690039A1 publication Critical patent/EA201690039A1/ru
Publication of EA029499B1 publication Critical patent/EA029499B1/ru
Publication of EA029499B9 publication Critical patent/EA029499B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Согласно изобретению предложены соединения формулы I или его фармацевтически приемлемые соли и фармацевтические композиции, ингибирующие активность RORγ (родственных ретиноидным рецепторам сиротских рецепторов γ), содержащие эти соединения.
EA201690039A 2013-08-02 2014-07-24 Ингибиторы rorc2 и способы их применения EA029499B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861709P 2013-08-02 2013-08-02
PCT/IB2014/063383 WO2015015378A2 (en) 2013-08-02 2014-07-24 Rorc2 inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
EA201690039A1 EA201690039A1 (ru) 2016-08-31
EA029499B1 EA029499B1 (ru) 2018-04-30
EA029499B9 true EA029499B9 (ru) 2018-07-31

Family

ID=51570793

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690039A EA029499B9 (ru) 2013-08-02 2014-07-24 Ингибиторы rorc2 и способы их применения

Country Status (42)

Country Link
US (6) US20160046597A1 (ru)
EP (2) EP3428160A1 (ru)
JP (1) JP6224832B2 (ru)
KR (1) KR101821903B1 (ru)
CN (1) CN105492434B (ru)
AP (1) AP2016009017A0 (ru)
AR (1) AR097199A1 (ru)
AU (1) AU2014298017B2 (ru)
BR (1) BR112016001781A2 (ru)
CA (1) CA2919783C (ru)
CL (1) CL2016000235A1 (ru)
CR (1) CR20160047A (ru)
CU (2) CU24398B1 (ru)
CY (1) CY1120751T1 (ru)
DK (1) DK3027603T3 (ru)
DO (1) DOP2016000039A (ru)
EA (1) EA029499B9 (ru)
EC (1) ECSP16008797A (ru)
ES (1) ES2685839T3 (ru)
GE (1) GEP20186876B (ru)
GT (1) GT201600027A (ru)
HK (1) HK1219093A1 (ru)
HR (1) HRP20181291T1 (ru)
HU (1) HUE039972T2 (ru)
IL (1) IL243728B (ru)
LT (1) LT3027603T (ru)
MA (1) MA38810B1 (ru)
MD (1) MD20160007A2 (ru)
MX (1) MX2016001446A (ru)
NI (1) NI201600021A (ru)
PE (1) PE20160801A1 (ru)
PH (1) PH12016500140B1 (ru)
PL (1) PL3027603T3 (ru)
PT (1) PT3027603T (ru)
RS (1) RS57618B1 (ru)
SG (1) SG11201600200QA (ru)
SI (1) SI3027603T1 (ru)
TN (1) TN2016000040A1 (ru)
TW (2) TW201516041A (ru)
UA (1) UA115908C2 (ru)
UY (1) UY35687A (ru)
WO (1) WO2015015378A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
EP3250570A1 (en) * 2015-01-30 2017-12-06 Pfizer Inc Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
WO2016120850A1 (en) * 2015-01-30 2016-08-04 Pfizer Inc. Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof
CN104672121B (zh) * 2015-02-16 2017-10-24 上海华默西医药科技有限公司 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法
JP6549735B2 (ja) * 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN109206401B (zh) * 2017-06-29 2021-03-05 南京柯菲平盛辉制药有限公司 一类甲基-1H-吲唑类RORγ调节剂及其用途
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa
JP2022540200A (ja) 2019-07-11 2022-09-14 エスケイプ・バイオ・インコーポレイテッド Ｌｒｒｋ２阻害剤としてのインダゾールおよびアザインダゾール
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
EP4136068B1 (en) * 2020-04-16 2024-07-10 Basf Se A process for the preparation of 4-cyanobenzoyl chlorides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
PL322843A1 (en) * 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
CA2299286A1 (en) * 1997-08-09 1999-02-18 Laramie Mary Gaster Bicyclic compounds as ligands for 5-ht1 receptors
WO1999064044A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
JP2011513330A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
CA2816753A1 (en) * 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
EP2511263A1 (en) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013064231A1 (en) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
CN104603118B (zh) * 2012-05-31 2017-10-03 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2013171729A2 (en) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator

Also Published As

Publication number Publication date
PH12016500140A1 (en) 2016-04-18
HRP20181291T1 (hr) 2018-10-19
CY1120751T1 (el) 2019-12-11
EA201690039A1 (ru) 2016-08-31
EP3428160A1 (en) 2019-01-16
CN105492434A (zh) 2016-04-13
US20170233371A1 (en) 2017-08-17
PL3027603T3 (pl) 2019-03-29
CR20160047A (es) 2016-03-03
TWI652263B (zh) 2019-03-01
CN105492434B (zh) 2018-02-16
UA115908C2 (uk) 2018-01-10
TW201516041A (zh) 2015-05-01
EP3027603A2 (en) 2016-06-08
MX2016001446A (es) 2016-05-05
PH12016500140B1 (en) 2016-04-18
TW201733998A (zh) 2017-10-01
GT201600027A (es) 2019-09-20
PT3027603T (pt) 2018-10-11
US20180086736A1 (en) 2018-03-29
CU24398B1 (es) 2019-04-04
WO2015015378A3 (en) 2015-05-14
SI3027603T1 (sl) 2018-10-30
TN2016000040A1 (fr) 2017-07-05
NI201600021A (es) 2016-03-16
AU2014298017B2 (en) 2018-03-29
ES2685839T3 (es) 2018-10-11
KR20160037996A (ko) 2016-04-06
IL243728A0 (en) 2016-04-21
WO2015015378A2 (en) 2015-02-05
KR101821903B1 (ko) 2018-01-24
HK1219093A1 (zh) 2017-03-24
JP6224832B2 (ja) 2017-11-01
CU20160015A7 (es) 2016-09-30
AR097199A1 (es) 2016-02-24
BR112016001781A2 (pt) 2017-08-01
US20160046597A1 (en) 2016-02-18
US20190144429A1 (en) 2019-05-16
CL2016000235A1 (es) 2017-07-07
IL243728B (en) 2018-10-31
PE20160801A1 (es) 2016-08-24
CA2919783C (en) 2018-02-06
DOP2016000039A (es) 2016-06-15
GEP20186876B (en) 2018-07-10
MA38810A1 (fr) 2017-10-31
CA2919783A1 (en) 2015-02-05
RS57618B1 (sr) 2018-11-30
EP3027603B1 (en) 2018-07-18
CU24366B1 (es) 2018-10-04
LT3027603T (lt) 2018-08-10
MA38810B1 (fr) 2018-06-29
US20200039960A1 (en) 2020-02-06
MD20160007A2 (ru) 2016-06-30
AP2016009017A0 (en) 2016-01-31
DK3027603T3 (en) 2018-09-17
HUE039972T2 (hu) 2019-02-28
EA029499B1 (ru) 2018-04-30
JP2016528226A (ja) 2016-09-15
SG11201600200QA (en) 2016-02-26
US20180282304A1 (en) 2018-10-04
UY35687A (es) 2015-02-27
AU2014298017A1 (en) 2016-02-11
CU20160145A7 (es) 2017-02-02
ECSP16008797A (es) 2017-08-31

Similar Documents

Publication Publication Date Title
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EA033689B9 (ru) Ингибиторы g12c kras
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
PH12016502353A1 (en) Pharmaceutical composition
IN2014DN10670A (ru)
PH12016501462A1 (en) Neprilysin inhibitors
TW201613577A (en) Pharmaceutical combinations
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
WO2014153495A3 (en) Novel stat3 inhibitors
EA201692298A1 (ru) Производные карбоксамидов
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
PH12016502247A1 (en) Carboxamide derivatives
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU